1. Home
  2. BEAT vs AYTU Comparison

BEAT vs AYTU Comparison

Compare BEAT & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heartbeam Inc.

BEAT

Heartbeam Inc.

HOLD

Current Price

$0.43

Market Cap

27.7M

Sector

Technology

ML Signal

HOLD

Logo Aytu BioPharma Inc.

AYTU

Aytu BioPharma Inc.

HOLD

Current Price

$2.15

Market Cap

27.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAT
AYTU
Founded
2015
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.7M
27.4M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
BEAT
AYTU
Price
$0.43
$2.15
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
3
Target Price
$5.63
$9.33
AVG Volume (30 Days)
305.7K
20.6K
Earning Date
05-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
15.07
N/A
EPS
N/A
N/A
Revenue
N/A
$27,632,080.00
Revenue This Year
N/A
N/A
Revenue Next Year
$315.97
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
277.47
52 Week Low
$0.39
$1.65
52 Week High
$4.00
$3.07

Technical Indicators

Market Signals
Indicator
BEAT
AYTU
Relative Strength Index (RSI) 41.03 47.53
Support Level $0.39 $2.07
Resistance Level $0.52 $2.33
Average True Range (ATR) 0.03 0.11
MACD 0.00 -0.01
Stochastic Oscillator 38.32 49.00

Price Performance

Historical Comparison
BEAT
AYTU

About BEAT Heartbeam Inc.

HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.

Share on Social Networks: